JDRF Awards $9 Million US for Phase 3 Type 1 Diabetes Kidney Disease
New York, New York and Montreal, Quebec--(Newsfile Corp. - January 22, 2024) - JDRF, the leading global type 1 diabetes (T1D) research and
Source: thewhig.com
David Cherney News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from David Cherney. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In David Cherney Today - Breaking & Trending Today
Drug Protects Kidneys, Heart in Diabetic Patients
A recent Canadian study has found that a drug prescribed to treat heart failure could protect kidney and heart health in individuals with type 2 diabetes and chronic kidney disease. Results from the study were presented on November 4, at ASN Kidney Week 2023 organized by the American Society of Nephrology, in Philadelphia. The study of a drug named “Sotagliflozin”, which has been approved by the FDA in May as a heart failure treatment, also involved non-diabetic patients.
Source: aawsat.com
Sotagliflozin May Slow CKD Progression in Diabetic Kidney Disease
Sotagliflozin, a dual SGLT 1 and 2 inhibitor, appears as effective in reducing kidney outcomes as other SGLT2 inhibitors. An analysis of data from the SCORED trial supports that sotagliflozin can lower the risk for chronic kidney disease (CKD) progression.
Source: endocrinologyadvisor.com
Sotagliflozin May Slow CKD Progression in Diabetic Kidney Disease
An analysis of data from the SCORED trial supports that sotagliflozin can lower the risk for chronic kidney disease (CKD) progression.
Source: empr.com
Sotagliflozin May Slow CKD Progression in Diabetic Kidney Disease
Sotagliflozin, a dual SGLT 1 and 2 inhibitor, appears as effective in reducing kidney outcomes as other SGLT2 inhibitors. An analysis of data from the SCORED trial supports that sotagliflozin can lower the risk for chronic kidney disease (CKD) progression.
Source: renalandurologynews.com